Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02352753 · ClinicalTrials.gov registry record · Phase 3
Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of Denosumab in Children w/ OI
A Phase 3 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 3
- Development phase
- 153
- Enrollment target
NCT02352753 is a Phase 3 study that was terminated before completion, run by Amgen. The registered enrollment target is 153 participants.
The verdict
NCT02352753, a Phase 3 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 153 participants
- Enrollment target
Study Summary
This is a prospective, multicenter, single-arm study in children 2 to 17 years of age with OI to evaluate efficacy and safety of denosumab.
Interventions
- DRUG Denosumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2015-06-24 |
| Est. Completion | 2022-03-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02352753
The ClinicalTrials.gov registry entry for NCT02352753 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Denosumab is the first listed.
NCT02352753 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02352753 about?
NCT02352753 is a clinical study titled "Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of Denosumab in Children w/ OI". This is a prospective, multicenter, single-arm study in children 2 to 17 years of age with OI to evaluate efficacy and safety of denosumab.
What is the current status of trial NCT02352753?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 153 participants. The study started on 2015-06-24. Estimated completion is 2022-03-26.
What interventions are being tested in trial NCT02352753?
The interventions under investigation include: Denosumab (DRUG).
Who is sponsoring clinical trial NCT02352753?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.